Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diego D Manavella

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The Journal of Obstetrics and Gynaecology Research|September 25, 2018
Recent advances in fertility preservationMarie-Madeleine Dolmans, Diego D Manavella
Minerva Ginecologica|April 13, 2018
Techniques for ovarian tissue transplantation and resultsJacques Donnez, Diego D Manavella, Marie-Madeleine Dolmans
Cancers|November 11, 2022
Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive OutcomesLevent Mutlu, Diego D Manavella, Giuseppe Gullo, et al.
Gynecologic Oncology|January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionDennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Gynecologic Oncology|May 31, 2022
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neuGhanshyam Yadav, Dana M Roque, Stefania Bellone, et al.
Clinical & Experimental Metastasis|June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology|November 28, 2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaJustin Harold, Stefania Bellone, Diego D Manavella, et al.
Gynecologic Oncology|May 22, 2022
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitorJoan R Tymon-Rosario, Paola Manara, Diego D Manavella, et al.
Molecular Cancer Therapeutics|September 7, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous CarcinomaLevent Mutlu, Diego D Manavella, Stefania Bellone, et al.
Gynecologic Oncology|December 16, 2022
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorDiego D Manavella, Blair McNamara, Justin Harold, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The Journal of Obstetrics and Gynaecology Research|September 25, 2018
Recent advances in fertility preservationMarie-Madeleine Dolmans, Diego D Manavella
Minerva Ginecologica|April 13, 2018
Techniques for ovarian tissue transplantation and resultsJacques Donnez, Diego D Manavella, Marie-Madeleine Dolmans
Cancers|November 11, 2022
Endometrial Cancer in Reproductive Age: Fertility-Sparing Approach and Reproductive OutcomesLevent Mutlu, Diego D Manavella, Giuseppe Gullo, et al.
Gynecologic Oncology|January 7, 2023
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expressionDennis Mauricio, Stefania Bellone, Levent Mutlu, et al.
Gynecologic Oncology|May 31, 2022
Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2/neuGhanshyam Yadav, Dana M Roque, Stefania Bellone, et al.
Clinical & Experimental Metastasis|June 22, 2024
Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2Levent Mutlu, Blair McNamara, Stefania Bellone, et al.
Gynecologic Oncology|November 28, 2022
Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcomaJustin Harold, Stefania Bellone, Diego D Manavella, et al.
Gynecologic Oncology|May 22, 2022
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitorJoan R Tymon-Rosario, Paola Manara, Diego D Manavella, et al.
Molecular Cancer Therapeutics|September 7, 2023
In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous CarcinomaLevent Mutlu, Diego D Manavella, Stefania Bellone, et al.
Gynecologic Oncology|December 16, 2022
Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitorDiego D Manavella, Blair McNamara, Justin Harold, et al.
Pageof 1